OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 213.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.69M |
| Shares Out | 13.34M |
| EPS (ttm) | -3.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,642 |
| Open | 16.20 |
| Previous Close | 16.39 |
| Day's Range | 15.89 - 16.33 |
| 52-Week Range | 9.80 - 77.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.50 (+134.38%) |
| Earnings Date | Nov 7, 2024 |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. [Read more]
Analyst Forecast
According to 2 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price forecast is $37.5, which is an increase of 134.38% from the latest price.
News
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...